{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:33:28Z","timestamp":1771382008985,"version":"3.50.1"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cancer is a leading cause of mortality worldwide, with most conventional treatments lacking efficacy and having significant challenges like drug resistance. Finding new molecules is quite challenging in terms of cost, time and setbacks. Hence, drug repurposing is considered sensible for skipping the long process of drug development. Dibenzazepine carboxamides, as traditional anticonvulsants, primarily function by blocking voltage-gated sodium channels, which not only mitigate seizures but also influence mood disorders through modulation of serotonin and dopamine. Recent studies have uncovered their anticancer properties, demonstrated by both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> experiments. This review comprehensively examines dibenzazepine\u2019s pharmacodynamics, pharmacokinetics, and clinical applications, focusing on their emerging role in oncology. By highlighting the anticancer mechanisms of action\u2014including apoptosis induction, inhibition of HDAC, Wnt\/\u03b2-Catenin signaling, and Voltage-gated sodium channels, we suggest further research to fully elucidate their therapeutic potential and application in cancer treatment.<\/jats:p>","DOI":"10.3389\/fphar.2025.1564911","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:13:02Z","timestamp":1743149582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The potential of dibenzazepine carboxamides in cancer therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Nastaran","family":"Afsordeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safura","family":"Pournajaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Mirnajafi-Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Pourgholami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","first-page":"2045","article-title":"Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells","volume":"21","author":"Abdul","year":"2001","journal-title":"Anticancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1186\/s12885-024-12840-3","article-title":"Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model","volume":"24","author":"Afsordeh","year":"2024","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e37230","DOI":"10.5812\/ircmj.37230","article-title":"Comparison of anticancer effects of carbamazepine and valproic acid","volume":"18","author":"Akbarzadeh","year":"2016","journal-title":"Iran. Red. Crescent Med. J."},{"key":"B4","first-page":"1","volume-title":"Anticonvulsant agents: carbamazepine, oxcarbazepine, and eslicarbazepine acetate. NeuroPsychopharmacotherapy","author":"Aledo-Serrano","year":"2020"},{"key":"B5","article-title":"Carbamazepine toxicity","volume-title":"StatPearls","author":"Al Khalili","year":"2023"},{"key":"B6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/9781444316667.ch38","article-title":"Eslicarbazepine acetate","volume-title":"The treatment of epilepsy","author":"Almeida","year":"2009"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"B8","first-page":"40","article-title":"Carbamazepine to treat primary nocturnal enuresis: double-blind study","volume":"5","author":"Al-Waili","year":"2000","journal-title":"Eur. J. Med. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/a:1014814924965","article-title":"Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024","volume":"27","author":"Ambr\u00f3sio","year":"2002","journal-title":"Neurochem. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1007\/s11033-023-08568-1","article-title":"The evidence for repurposing anti-epileptic drugs to target cancer","volume":"50","author":"Aroosa","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15376516.2016.1273430","article-title":"Oxcarbazepine-induced cytotoxicity and genotoxicity in human lymphocyte cultures with or without metabolic activation","volume":"27","author":"Atl\u0131 \u015eekero\u011flu","year":"2017","journal-title":"Toxicol. Mech. Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2472-095x.1000112","article-title":"Bipolar disorders and carbamazepine: pharmacokinetics, pharmacodynamics, therapeutic effects and indications of carbamazepine: review of articles","volume":"1","author":"Ayano","year":"2016","journal-title":"J. Neuropsychopharmacol. Ment. Health"},{"key":"B13","first-page":"3098","article-title":"Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways","volume":"11","author":"Bahrami","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116688","DOI":"10.1016\/j.envpol.2021.116688","article-title":"Carbamazepine induces hepatotoxicity in zebrafish by inhibition of the Wnt\/\u03b2-catenin signaling pathway","volume":"276","author":"Bai","year":"2021","journal-title":"Environ. Pollut."},{"key":"B15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1176\/ajp.137.7.782","article-title":"Carbamazepine in manic-depressive illness: a new treatment","volume":"137","author":"Ballenger","year":"1980","journal-title":"Am. J. psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s11064-021-03349-3","article-title":"Exercise improved the anti-epileptic effect of carbamazepine through gaba enhancement in epileptic rats","volume":"46","author":"Barzroodi Pour","year":"2021","journal-title":"Neurochem. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0165-0327(02)00407-X","article-title":"Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode","volume":"79","author":"Benedetti","year":"2004","journal-title":"J. Affect. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1535-7511.2009.01337.x","article-title":"Eslicarbazepine acetate: a well-kept secret?","volume":"10","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Curr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s00415-018-8857-0","article-title":"Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study","volume":"265","author":"Berntsson","year":"2018","journal-title":"J. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.lfs.2005.01.003","article-title":"Carbamazepine is an inhibitor of histone deacetylases","volume":"76","author":"Beutler","year":"2005","journal-title":"Life Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"154909","DOI":"10.1016\/j.prp.2023.154909","article-title":"Voltage-gated sodium channels in cancer and their specific inhibitors","volume":"251","author":"Bian","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug","volume":"22","author":"Blaheta","year":"2002","journal-title":"Med. Res. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2174\/0929867023369763","article-title":"Valproate and valproate-analogues: potent tools to fight against cancer","volume":"9","author":"Blaheta","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(62)91847-0","article-title":"Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883)","volume":"1","author":"Blom","year":"1962","journal-title":"Lancet"},{"key":"B28","first-page":"169","article-title":"Automatisms of long duration and epileptic fugues in adults","volume":"122","author":"Bonduelle","year":"1964","journal-title":"Ann. Med. Psychol. Paris."},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tem.2009.08.005","article-title":"WNT signaling in ovarian follicle biology and tumorigenesis","volume":"21","author":"Boyer","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1113\/jphysiol.2006.106906","article-title":"Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line","volume":"573","author":"Brackenbury","year":"2006","journal-title":"J. Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"Cd013028","DOI":"10.1002\/14651858.CD013028.pub3","article-title":"Clonazepam monotherapy for treating people with newly diagnosed epilepsy","volume":"2","author":"Brigo","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-017-0441-0","article-title":"Sodium Channel blockers in the treatment of epilepsy","volume":"31","author":"Brodie","year":"2017","journal-title":"CNS Drugs"},{"key":"B33","first-page":"1549","article-title":"Carbamazepine for acute and chronic pain","volume":"73","author":"Buescher","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s12094-018-1892-6","article-title":"Choice of antiepileptic drugs affects the outcome in cancer patients with seizures","volume":"20","author":"Cacho-Diaz","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1242\/jcs.130013","article-title":"Functional expression of the voltage-gated Na+-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells","volume":"126","author":"Campbell","year":"2013","journal-title":"J. Cell Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1034\/j.1399-5618.2003.00047.x","article-title":"Oxcarbazepine: clinical experience with hospitalized psychiatric patients","volume":"5","author":"Centorrino","year":"2003","journal-title":"Bipolar Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.7150\/jca.19273","article-title":"FH535 inhibits proliferation and motility of colon cancer cells by targeting wnt\/\u03b2-catenin signaling pathway","volume":"8","author":"Chen","year":"2017","journal-title":"J. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1528-1157.1998.tb01290.x","article-title":"Carbamazepine-induced release of serotonin from rat hippocampus in vitro","volume":"39","author":"Dailey","year":"1998","journal-title":"Epilepsia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/cells12081200","article-title":"The antiepileptic drug oxcarbazepine inhibits the growth of patient-derived isocitrate dehydrogenase mutant glioma stem-like cells","volume":"12","author":"Dao Trong","year":"2023","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.pnpbp.2006.03.035","article-title":"A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder","volume":"30","author":"Davids","year":"2006","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0924-977x(97)00406-9","article-title":"Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans","volume":"7","author":"Delcker","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7314\/apjcp.2014.15.1.199","article-title":"Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin","volume":"15","author":"El Sharkawi","year":"2014","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/01480545.2021.2014859","article-title":"Carbamazepine-induced renal toxicity may be associated with oxidative stress and apoptosis in male rat","volume":"46","author":"Erdem Guzel","year":"2023","journal-title":"Drug Chem. Toxicol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/9781118936979.ch40","article-title":"Oxcarbazepine","volume-title":"The treatment of epilepsy","author":"Faught","year":"2015"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/MJT.0000000000001714","article-title":"Highest dose of eslicarbazepine for refractory secondary trigeminal neuralgia","volume":"10","author":"Fortuna","year":"2022","journal-title":"Am. J. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00003088-199528030-00003","article-title":"Levonorgestrel. Clinical pharmacokinetics","volume":"28","author":"Fotherby","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/17512433.2018.1486707","article-title":"Carbamazepine adverse drug reactions","volume":"11","author":"Fricke-Galindo","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","article-title":"Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures","volume":"17","author":"Galiana","year":"2017","journal-title":"Drugs R. D."},{"key":"B52","doi-asserted-by":"publisher","first-page":"110114","DOI":"10.1016\/j.biopha.2020.110114","article-title":"Recent advances in the molecular mechanism of thalidomide teratogenicity","volume":"127","author":"Gao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.33588\/rn.71s01.2020562","article-title":"The role of eslicarbazepine acetate in the treatment of focal-onset epilepsy in pediatric age: practical issues","volume":"71","author":"Garc\u00eda-Pe\u00f1as","year":"2020","journal-title":"Rev. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eplepsyres.2016.03.004","article-title":"Weight gain in children on oxcarbazepine monotherapy","volume":"122","author":"Garoufi","year":"2016","journal-title":"Epilepsy Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0896-6273(00)00116-1","article-title":"Nomenclature of voltage-gated sodium channels","volume":"28","author":"Goldin","year":"2000","journal-title":"Neuron"},{"key":"B56","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.jchemneu.2019.101729","article-title":"Prenatal exposure to oxcarbazepine increases hippocampal apoptosis in rat offspring","volume":"103","author":"Gonz\u00e1lez-Maciel","year":"2020","journal-title":"J. Chem. Neuroanat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/j.1528-1167.2007.01263.x","article-title":"Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate\u2010induced epilepsy: comparison of intraperitoneal injections with drug\u2010in\u2010food protocols","volume":"48","author":"Grabenstatter","year":"2007","journal-title":"Epilepsia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.3390\/cancers12103068","article-title":"Ion channels as therapeutic targets in high grade gliomas","volume":"12","author":"Griffin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.3390\/cimb45050248","article-title":"AhR and wnt\/\u03b2-catenin signaling pathways and their interplay","volume":"45","author":"Grishanova","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000026528","article-title":"Modulation of calcium and potassium currents by lamotrigine","volume":"38","author":"Grunze","year":"1998","journal-title":"Neuropsychobiology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.neulet.2018.03.047","article-title":"Abnormal changes in voltage-gated sodium channels subtypes Na(V)1.1, Na(V)1.2, Na(V)1.3, Na(V)1.6 and CaM\/CaMKII pathway in low-grade astrocytoma","volume":"674","author":"Guan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/epd2.20146","article-title":"Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: a safety perspective","volume":"25","author":"Guedes","year":"2023","journal-title":"Epileptic Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","article-title":"Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme","volume":"118","author":"Guthrie","year":"2013","journal-title":"J. Neurosurg."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1158\/1055-9965.EPI-08-0646","article-title":"Cancer risk in long-term users of valproate: a population-based case-control study","volume":"18","author":"Hallas","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ijc.26210","article-title":"Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer","volume":"130","author":"Hernandez-Plata","year":"2012","journal-title":"Int. J. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1017\/S1461145704004651","article-title":"A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder","volume":"7","author":"Hirschfeld","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1158\/0008-5472.CAN-10-1169","article-title":"Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion","volume":"70","author":"House","year":"2010","journal-title":"Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1573407211666150910202200","article-title":"Pharmacological and biological activities of benzazepines: an overview","volume":"11","author":"Shah","year":"2015","journal-title":"Curr. Bioact. Compd."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1021\/acs.jmedchem.2c01975","article-title":"Advances in epilepsy: mechanisms, clinical trials, and drug therapies","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/cells8111460","article-title":"Carbamazepine enhances adipogenesis by inhibiting wnt\/\u03b2-catenin expression","volume":"8","author":"Im","year":"2019","journal-title":"Cells"},{"key":"B72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.arcmed.2020.10.021","article-title":"Drug repurposing: considerations to surpass while Re-directing old compounds for new treatments","volume":"52","author":"Ju\u00e1rez-L\u00f3pez","year":"2021","journal-title":"Arch. Med. Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.bjp.0704104","article-title":"Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca2+\u2010and K+\u2010evoked serotonin release","volume":"133","author":"Kawata","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.21873\/invivo.6614","article-title":"Ionizing irradiation protection and mitigation of murine cells by carbamazepine is p53 and autophagy independent","volume":"26","author":"Kim","year":"2012","journal-title":"Vivo"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3109\/09553002.2011.587860","article-title":"The autophagy-inducing drug carbamazepine is a radiation protector and mitigator","volume":"87","author":"Kim","year":"2011","journal-title":"Int. J. Radiat. Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.taap.2013.10.006","article-title":"Carbamazepine suppresses calpain-mediated autophagy impairment after ischemia\/reperfusion in mouse livers","volume":"273","author":"Kim","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00228-005-0940-7","article-title":"Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects","volume":"61","author":"Kim","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5455\/msm.2015.27.167-171","article-title":"Prevalence of side effects treatment with carbamazepine and other antiepileptics in patients with epilepsy","volume":"27","author":"Koliqi","year":"2015","journal-title":"Mater Sociomed."},{"key":"B79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-211-99481-8_4","article-title":"Seizures in patients with low-grade gliomas--incidence, pathogenesis, surgical management, and pharmacotherapy","volume":"35","author":"Kurzwelly","year":"2010","journal-title":"Adv. Tech. Stand Neurosurg."},{"key":"B80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40120-018-0111-2","article-title":"Dibenzazepine agents in epilepsy: How does eslicarbazepine acetate differ?","volume":"7","author":"Lawthom","year":"2018","journal-title":"Neurol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"Lee","year":"2016","journal-title":"J. Neurooncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"555047","DOI":"10.3389\/fphar.2020.555047","article-title":"Inhibitory effect of eslicarbazepine acetate and S-licarbazepine on Na(v)1.5 channels","volume":"11","author":"Leslie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1124\/dmd.107.019554","article-title":"Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin","volume":"36","author":"Lu","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/cancers13081953","article-title":"An alternative pipeline for glioblastoma therapeutics: a systematic review of drug repurposing in glioblastoma","volume":"13","author":"Lyne","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B87","article-title":"Carbamazepine","volume-title":"StatPearls","author":"Maan","year":"2023"},{"key":"B88","article-title":"Carbamazepine, in StatPearls. Treasure island (FL) ineligible companies","volume-title":"Disclosure: truc vi Duong declares no relevant financial relationships with ineligible companies. Disclosure: abdolreza Saadabadi declares no relevant financial relationships with ineligible companies","author":"Maan","year":"2024"},{"key":"B89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsomega.2c05821","article-title":"Drug repurposing: a new hope in drug discovery for prostate cancer","volume":"8","author":"Malik","year":"2023","journal-title":"ACS Omega"},{"key":"B90","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s1471-4892(03)00084-5","article-title":"Histone deacetylases","volume":"3","author":"Marks","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"B92","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.jcp.0000186739.22395.6b","article-title":"Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial","volume":"25","author":"Mattes","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B94","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1517\/14656566.8.5.649","article-title":"Oxcarbazepine in bipolar disorder: a critical review of the literature","volume":"8","author":"Mazza","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11010-010-0651-y","article-title":"Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90","volume":"348","author":"Meng","year":"2011","journal-title":"Mol. Cell Biochem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/13543780802635107","article-title":"Eslicarbazepine acetate: a new option for the treatment of focal epilepsy","volume":"18","author":"Mestre","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WNF.0b013e318271220b","article-title":"Eslicarbazepine acetate in the management of refractory bipolar disorder","volume":"35","author":"Nath","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"Cd011412","DOI":"10.1002\/14651858.CD011412.pub4","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B99","first-page":"1139","volume-title":"Sadock\u2019s Comprehensive textbook of psychiatry","author":"Norman","year":"2009"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.3390\/ijms20153727","article-title":"Carbamazepine attenuates astroglial L-glutamate release induced by pro-inflammatory cytokines via chronically activation of adenosine A(2A) receptor","volume":"20","author":"Okada","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.toxlet.2021.07.018","article-title":"Oxcarbazepine induces mitotic catastrophe and apoptosis in NRK-52E proximal tubular cells","volume":"350","author":"Ota","year":"2021","journal-title":"Toxicol. Lett."},{"key":"B102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bone.2018.05.011","article-title":"The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats","volume":"113","author":"Parveen","year":"2018","journal-title":"Bone"},{"key":"B103","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejps.2018.05.026","article-title":"Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: role of HDAC inhibition","volume":"121","author":"Patel","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1124\/dmd.107.019562","article-title":"Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine","volume":"36","author":"Pearce","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1124\/dmd.30.11.1170","article-title":"Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites","volume":"30","author":"Pearce","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"B106","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","article-title":"Carbamazepine side effects in children and adults","volume":"28","author":"Pellock","year":"1987","journal-title":"Epilepsia"},{"key":"B107","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.yebeh.2015.05.036","article-title":"Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion","volume":"50","author":"Peltola","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B108","doi-asserted-by":"publisher","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/14737175.7.6.617","article-title":"Oxcarbazepine in the treatment of bipolar and schizoaffective disorders","volume":"7","author":"Popova","year":"2007","journal-title":"Expert Rev. Neurother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2012.12.031","article-title":"Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways","volume":"129","author":"Pourgholami","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","article-title":"Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice","volume":"12","author":"Pourgholami","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B113","first-page":"3470","volume-title":"FDA approval of oxcarbazepine","author":"Preboth","year":"2000"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"},{"key":"B115","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/0920-1211(87)90003-9","article-title":"Comparison of oxcarbazepine and carbamazepine: a double-blind study","volume":"1","author":"Reinikainen","year":"1987","journal-title":"Epilepsy Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.seizure.2019.12.022","article-title":"Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice","volume":"75","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"B117","doi-asserted-by":"publisher","first-page":"183","DOI":"10.12775\/jehs.2022.12.11.024","article-title":"Clinical significancy of WNT pathway inhibition in various cancers","volume":"12","author":"Rogaczewski","year":"2022","journal-title":"J. Educ. Health Sport"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24875\/RIC.22000260","article-title":"Molecular and genetic mechanisms of neurotoxicity during anti-seizure medications use","volume":"75","author":"Rubio","year":"2023","journal-title":"Rev. Invest Clin."},{"key":"B119","volume-title":"Compre-hensive textbook of psychiatry","author":"Sadock","year":"2009"},{"key":"B120","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ijc.33535","article-title":"Antiepileptic drugs and prostate cancer risk in the Finnish randomized study of screening for prostate cancer","volume":"149","author":"Salminen","year":"2021","journal-title":"Int. J. Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41416-022-01817-3","article-title":"Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"127","author":"Salminen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10552-016-0737-2","article-title":"Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study","volume":"27","author":"Salminen","year":"2016","journal-title":"Cancer Causes Control"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ejp.1192","article-title":"Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia","volume":"22","author":"Sanchez\u2010Larsen","year":"2018","journal-title":"Eur. J. pain"},{"key":"B124","doi-asserted-by":"publisher","first-page":"127","DOI":"10.15252\/emmm.201404137","article-title":"Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion","volume":"7","author":"Schiebler","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in man","volume":"16","author":"Sch\u00fctz","year":"1986","journal-title":"Xenobiotica"},{"key":"B126","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10637-024-01418-2","article-title":"Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status","volume":"42","author":"Shaykevich","year":"2024","journal-title":"Invest New Drugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/seiz.2000.0391","article-title":"Oxcarbazepine: a review","volume":"9","author":"Shorvon","year":"2000","journal-title":"Seizure"},{"key":"B129","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1528-1167.2009.02042.x","article-title":"Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009","volume":"50","author":"Shorvon","year":"2009","journal-title":"Epilepsia"},{"key":"B130","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00004583-199603000-00017","article-title":"Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis","volume":"35","author":"Silva","year":"1996","journal-title":"J. Am. Acad. Child and Adolesc. Psychiatry"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e00124","DOI":"10.1002\/prp2.124","article-title":"Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action","volume":"3","author":"Soares\u2010Da\u2010Silva","year":"2015","journal-title":"Pharmacol. Res. and Perspect."},{"key":"B132","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12029-019-00286-x","article-title":"Carbamazepine, a histone deacetylase inhibitor induces apoptosis in human colon adenocarcinoma cell line HT-29","volume":"51","author":"Sohaib","year":"2020","journal-title":"J. Gastrointest. Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"250","DOI":"10.26355\/eurrev_201801_14126","article-title":"Oxcarbazepine causes neurocyte apoptosis and developing brain damage by triggering Bax\/Bcl-2 signaling pathway mediated caspase 3 activation in neonatal rats","volume":"22","author":"Song","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","article-title":"Clinically significant pharmacokinetic drug interactions with carbamazepine. An update","volume":"31","author":"Spina","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CEJ.0b013e32834a7e6f","article-title":"Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer","volume":"21","author":"Stettner","year":"2012","journal-title":"Eur. J. Cancer Prev."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1007\/s00415-020-10379-4","article-title":"Anti-seizure medication is not associated with an increased risk to develop cancer in epilepsy patients","volume":"268","author":"Stritzelberger","year":"2021","journal-title":"J. Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2147\/NDT.S86765","article-title":"Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy","volume":"12","author":"Tambucci","year":"2016","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"B139","doi-asserted-by":"publisher","first-page":"s37","DOI":"10.1111\/j.1528-1157.1999.tb00918.x","article-title":"Oxcarbazepine","volume":"40","author":"Tecoma","year":"1999","journal-title":"Epilepsia"},{"key":"B140","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00204-013-1183-5","article-title":"Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model","volume":"88","author":"Teichmann","year":"2014","journal-title":"Arch. Toxicol."},{"key":"B141","first-page":"S81","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Tolou-Ghamari","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12939-023-02067-2","article-title":"A critical review and analysis of the context, current burden, and application of policy to improve cancer equity in Ghana","volume":"22","author":"Tuck","year":"2023","journal-title":"Int. J. Equity Health"},{"key":"B143","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"Van Breemen","year":"2007","journal-title":"Lancet Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.14841","article-title":"The role of adenosine receptors in mood and anxiety disorders","volume":"151","author":"Van Calker","year":"2019","journal-title":"J. Neurochem."},{"key":"B145","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0922-4106(91)90111-t","article-title":"Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses","volume":"206","author":"Van Calker","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.10.005","article-title":"Eslicarbazepine acetate: an update on efficacy and safety in epilepsy","volume":"108","author":"Verrotti","year":"2014","journal-title":"Epilepsy Res."},{"key":"B147","article-title":"Carbamazepine and oxcarbazepine","volume":"453","author":"Wang","year":"2013","journal-title":"Essentials Clin. Psychopharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/ane.13248","article-title":"The evidence for switching dibenzazepines in people with epilepsy","volume":"142","author":"Watkins","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"B149","doi-asserted-by":"publisher","first-page":"CD005451","DOI":"10.1002\/14651858.CD005451.pub3","article-title":"Carbamazepine for chronic neuropathic pain and fibromyalgia in adults","volume":"2014","author":"Wiffen","year":"2014","journal-title":"Cochrane database Syst. Rev."},{"key":"B150","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10198-023-01623-5","article-title":"Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis","volume":"25","author":"Wills","year":"2024","journal-title":"Eur. J. Health Econ."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1002\/ijc.30381","article-title":"Voltage-gated sodium channel Nav 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1","volume":"139","author":"Xia","year":"2016","journal-title":"Int. J. Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-017-0622-y","article-title":"Ion channels or aquaporins as novel molecular targets in gastric cancer","volume":"16","author":"Xia","year":"2017","journal-title":"Mol. Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"749930","DOI":"10.3389\/fphar.2021.749930","article-title":"Carbamazepine induces platelet apoptosis and thrombocytopenia through protein kinase A","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3892\/or.2022.8431","article-title":"Anti-tumor effects of anti-epileptic drugs in malignant glioma cells","volume":"48","author":"Yagi","year":"2022","journal-title":"Oncol. Rep."},{"key":"B155","doi-asserted-by":"publisher","first-page":"116245","DOI":"10.1016\/j.envpol.2020.116245","article-title":"Carbamazepine at environmentally relevant concentrations caused DNA damage and apoptosis in the liver of Chinese rare minnows (Gobiocypris rarus) by the Ras\/Raf\/ERK\/p53 signaling pathway","volume":"270","author":"Yan","year":"2021","journal-title":"Environ. Pollut."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/DDDT.S149307","article-title":"Vicenin-2 inhibits Wnt\/\u03b2-catenin signaling and induces apoptosis in HT-29 human colon cancer cell line","volume":"12","author":"Yang","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3923\/pjbs.2023.419.426","article-title":"Effect of voltage-gated sodium channel inhibitors on the metastatic behavior of prostate cancer cells: a meta-analysis","volume":"26","author":"Yildirim-Kahriman","year":"2023","journal-title":"Pak J. Biol. Sci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3389\/fphar.2020.00984","article-title":"Targeting \u03b2-catenin signaling by natural products for cancer prevention and therapy","volume":"11","author":"Yu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"B161","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","article-title":"Histone deacetylase inhibitors and cell death","volume":"71","author":"Zhang","year":"2014","journal-title":"Cell. Mol. life Sci."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/cns.12855","article-title":"Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model","volume":"24","author":"Zhang","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1021\/acs.jmedchem.9b02020","article-title":"Antiepileptic drug carbamazepine binds to a novel pocket on the Wnt receptor frizzled-8","volume":"63","author":"Zhao","year":"2020","journal-title":"J. Med. Chem."},{"key":"B164","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0920-1211(02)00053-0","article-title":"Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice","volume":"51","author":"Zhen Sun","year":"2002","journal-title":"Epilepsy Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/00207454.2020.1759590","article-title":"Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experience","volume":"131","author":"Zoccarato","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.critrevonc.2024.104297","article-title":"Cancer of unknown primary and the \u00abseed and soil\u00bb hypothesis","volume":"196","author":"Zolotykh","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:14:01Z","timestamp":1743149641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1564911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":167,"alternative-id":["10.3389\/fphar.2025.1564911"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1564911","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1564911"}}